Witty: GSK to buck trend of pulling out of UK

Stateless? Transnational? A citizen of the world? Forget it. In what must be a relief to UK officials, GlaxoSmithKline CEO Andrew Witty promises his company is resolutely British, and that's not negotiable. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.